BlackRock’s Verona Pharma VRNA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-3,826,710
| Closed | -$408M | – | 5649 |
|
|
2025
Q3 | $408M | Buy |
3,826,710
+3,483,014
| +1,013% | +$364M | 0.01% | 1229 |
|
|
2025
Q2 | $32.5M | Sell |
343,696
-146,836
| -30% | -$10.9M | ﹤0.01% | 2733 |
|
|
2025
Q1 | $31.1M | Buy |
490,532
+100,296
| +26% | +$6M | ﹤0.01% | 2664 |
|
|
2024
Q4 | $18.1M | Sell |
390,236
-44,502
| -10% | -$1.67M | ﹤0.01% | 3108 |
|
|
2024
Q3 | $12.5M | Buy |
434,738
+4,309
| +1% | +$106K | ﹤0.01% | 3289 |
|
|
2024
Q2 | $6.22M | Buy |
430,429
+48,712
| +13% | +$711K | ﹤0.01% | 3607 |
|
|
2024
Q1 | $6.14M | Buy |
381,717
+17,104
| +5% | +$296K | ﹤0.01% | 3591 |
|
|
2023
Q4 | $7.25M | Buy |
364,613
+28,810
| +9% | +$425K | ﹤0.01% | 3534 |
|
|
2023
Q3 | $5.47M | Sell |
335,803
-32,757
| -9% | -$631K | ﹤0.01% | 3621 |
|
|
2023
Q2 | $7.79M | Buy |
368,560
+21,334
| +6% | +$455K | ﹤0.01% | 3530 |
|
|
2023
Q1 | $6.97M | Buy |
347,226
+1,901
| +0.6% | +$41K | ﹤0.01% | 3491 |
|
|
2022
Q4 | $9.02M | Buy |
345,325
+345,312
| +2,656,246% | +$4.6M | ﹤0.01% | 3446 |
|
|
2022
Q3 | $0 | Hold |
13
| – | – | ﹤0.01% | 5941 |
|
|
2022
Q2 | $0 | Buy |
+13
| New | +$56 | ﹤0.01% | 5996 |
|
|
2021
Q4 | – | Sell |
-245,594
| Closed | -$1.35M | – | 5869 |
|
|
2021
Q3 | $1.35M | Sell |
245,594
-4,347
| -2% | -$25.3K | ﹤0.01% | 4479 |
|
|
2021
Q2 | $1.64M | Buy |
+249,941
| New | +$1.73M | ﹤0.01% | 4356 |
|
Other funds holding VRNA
BlackRock's VRNA Position: Q4 2025 in Review
BlackRock sold out of Verona Pharma (VRNA) in Q4 2025, closing a stake of 3,826,710 shares — an estimated $408M sold.
BlackRock first reported a position in VRNA in Q2 2021 and held it in 16 quarters. The position peaked at $408M in Q3 2025. 1 fund tracked by Wall St. Rank holds VRNA as of Q4 2025.
- BlackRock reported no remaining Verona Pharma position as of Q4 2025 after selling out during the quarter.
- BlackRock sold 3,826,710 Verona Pharma shares in Q4 2025, an estimated $408M.
- BlackRock first reported a position in Verona Pharma in Q2 2021 and held it in 16 quarters.
- BlackRock's Verona Pharma position peaked at $408M in Q3 2025.
- 1 fund tracked by Wall St. Rank held Verona Pharma as of Q4 2025.
Based on BlackRock's 13F filing for Q4 2025, filed 12 Feb 2026.